Scarica l'app Stockscreener
0.00
100.00%
-2.38
Dopo l'orario di chiusura:
2.34
2.34
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SAVA Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$2.38
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$114.97M
Reddito:
-
Utile/perdita netta:
$-97.22M
Rapporto P/E:
0.00
EPS:
-1.38
Flusso di cassa netto:
$-82.44M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$4.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Nome
Cassava Sciences Inc
Settore
Industria
Telefono
512-501-2444
Indirizzo
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
0.00 | 114.97M | 0 | -97.22M | -82.44M | -1.38 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
| 2021-04-27 | Iniziato | B. Riley Securities | Buy |
| 2021-02-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | Downgrade | Maxim Group | Buy → Hold |
| 2020-01-10 | Reiterato | Maxim Group | Buy |
Mostra tutto
Cassava Sciences Inc Borsa (SAVA) Ultime notizie
Death Cross: What are the future prospects of Cassava Sciences Inc Equity WarrantPortfolio Gains Summary & Verified Chart Pattern Trade Signals - baoquankhu1.vn
FLNA|Cassava Sciences Ord Shs|Price:1.635|Chg%:-0.00 - TradingKey
FLNA|Cassava Sciences Ord Shs|Price:1.640|Chg%:-0.08 - TradingKey
If You Invested $1,000 in Cassava Sciences (SAVA) - Stock Titan
Trend Report: What is the dividend yield of Cassava Sciences Inc Equity Warrant2026 Geopolitical Influence & Entry and Exit Point Strategies - baoquankhu1.vn
Aug Chart Watch: Is Cassava Sciences Inc Equity Warrant trading at a discountWeekly Market Outlook & High Accuracy Swing Trade Signals - baoquankhu1.vn
Market Leaders: Can Cassava Sciences Inc Equity Warrant maintain its current growth rate2026 Levels & Low Risk Investment Opportunities - baoquankhu1.vn
Aug Update: Is Cassava Sciences Inc Equity Warrant subject to activist investor interestWatch List & Consistent Return Investment Signals - baoquankhu1.vn
RSI Check: What is the dividend yield of Cassava Sciences IncPortfolio Performance Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
SEC Moves To Set Up $40M Investor Fund In Cassava Case - Law360
Cassava Sciences Stock Rises 1.8% - National Today
Cassava Sciences (NASDAQ:SAVA) Stock Price Up 1.8%Here's What Happened - MarketBeat
FLNA Stock Price, News & Analysis - Stock Titan
RSI Check: Is Cassava Sciences Inc backed by strong institutional buying2026 PreEarnings & Fast Entry Momentum Alerts - baoquankhu1.vn
Cassava Sciences says DOJ has closed probe into allegations around its Alzheimer’s program - MSN
Dow Update: What is the dividend yield of Cassava Sciences Inc Equity WarrantInsider Selling & Proven Capital Preservation Tips - baoquankhu1.vn
Cassava Sciences, Inc. (FLNA) - Minichart
Cassava Sciences Inc Share PriceShare CFDs - FOREX.com
Energy Moves: What is Cassava Sciences Inc Equity Warrants book value per share - baoquankhu1.vn
SAVA PE Ratio & Valuation, Is SAVA Overvalued - Intellectia AI
ETF Watch: What are the future prospects of Cassava Sciences Inc Equity WarrantPortfolio Risk Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urg - GuruFocus
Cassava Sciences, Inc. Common Stock (FLNA) Competitors - Meyka
FOMO Trade: Does Cassava Sciences Inc Equity Warrant offer margin of safety2026 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
Trading Recap: Is Cassava Sciences Inc Equity Warrant subject to activist investor interest2026 Sentiment & Daily Stock Trend Watchlist - baoquankhu1.vn
Block Trades: Does Cassava Sciences Inc Equity Warrant have pricing powerMarket Sentiment Summary & Long-Term Growth Stock Strategies - baoquankhu1.vn
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - marketscreener.com
Cassava Sciences, Inc. Class Action: The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - marketscreener.com
Filana Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PX91 | US14817C1071 - marketscreener.com
Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your RightsSAVA - marketscreener.com
Filana Therapeutics Inc (FLNA-Q) Profile - The Globe and Mail
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - marketscreener.com
Filana Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SAVA * | US14817C1071 - marketscreener.com
FLNA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cassava Sciences Posts Earnings, Beats Estimates - National Today
Cassava Sciences (NASDAQ:SAVA) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Filana Therapeutics (NASDAQ: SAVA) pivots to TSC epilepsy amid FDA clinical hold - Stock Titan
Total equity of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Average basic shares outstanding of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Cassava Sciences, Inc. Cash Flow – BMV:FLNA - TradingView
Price to book ratio of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Free cash flow per share of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Long term debt to total equity ratio of Cassava Sciences, Inc. – BMV:FLNA - TradingView
Cassava Sciences, Inc. Earnings and Revenue – BMV:FLNA - TradingView
Cassava Sciences, Inc. Balance Sheet – BMV:FLNA - TradingView
ETFs Investing in Cassava Sciences, Inc. Stocks - TradingView
FLNA Forecast — Price Target — Prediction for 2027 - TradingView
Filana Therapeutics (NASDAQ: FLNA) pivots to TSC epilepsy amid $91M loss - Stock Titan
Biotech that ditched Alzheimer's drug pivots to epilepsy, slashes R&D 62% - Stock Titan
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Rate Cut: Can Cassava Sciences Inc beat the S P 500Global Markets & Growth Focused Entry Point Reports - baoquankhu1.vn
Cassava Sciences Inc Azioni (SAVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cassava Sciences Inc Azioni (SAVA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Barry Richard | President & CEO |
Nov 20 '25 |
Buy |
2.76 |
150,000 |
414,000 |
938,060 |
| Barry Richard | President & CEO |
Nov 19 '25 |
Buy |
2.75 |
73,385 |
201,809 |
788,060 |
| Cook Robert Christopher | Chief Operating & Legal Office |
Sep 30 '25 |
Buy |
2.91 |
13,725 |
39,940 |
13,725 |
| Barry Richard | President & CEO |
Sep 22 '25 |
Buy |
2.28 |
7,172 |
16,352 |
714,675 |
| Barry Richard | President & CEO |
Sep 18 '25 |
Buy |
2.24 |
190,633 |
426,424 |
660,195 |
| Barry Richard | President & CEO |
Sep 19 '25 |
Buy |
2.29 |
47,308 |
108,319 |
707,503 |
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):